Although the role of MAO-B inhibitors in treating fatigue has been extensively explored in both clinical and preclinical studies, our findings align with a recent systematic review and meta-analysis by Siciliano et al. [60], which highlighted the lack of effective pharmacological treatments specifically targeting fatigue in PD. This evidence concerns the gene MAOB and Parkinson disease.